2-hydroxybenzylamine (2-HOBA), a naturally occurring compound found in buckwheat, has potential for use as a nutrition supplement due to its ability to protect against the damaging effects of oxidative stress. In a series of rodent toxicity studies, 2-HOBA acetate was well-tolerated and did not produce any toxic effects over 28 or 90 days of repeated oral administration. However, it remained necessary to test the potential toxicity of 2-HOBA acetate in a non-rodent species. In this investigation, 2-HOBA acetate was orally administered to male and female New Zealand White Rabbits for 90 days at doses of 100, 500, and 1000 mg·kg BW −1 ·day −1 (n = 5 per sex/group). As previously observed in rodents, 2-HOBA acetate administration was well tolerated. No toxic effects of 2-HOBA acetate were detected in body weight, feed consumption, hematology, blood chemistry, urine chemistry, organ weights, gross pathology or histopathology. Based on these findings, the no-observed-adverseeffect-level of 2-HOBA acetate in rabbits was determined to be 1000 mg·kg BW −1 ·day −1
Introduction
γ-Ketoaldehydes are highly reactive lipid aldehydes that are created during prostaglandin formation (Iyer et al., 1989; Murthi et al., 1993) and arachidonic acid oxidation (Brame et al., 1999; Morrow et al., 1990; Salomon and Miller, 1985) . These aldehydes quickly form adducts with proteins (Davies et al., 2002) and lipids (Bernoud-Hubac et al., 2009; Sullivan et al., 2010) that can alter protein function and induce cellular stress, inflammation, and damage. Fortunately, 2-hydroxybenzylamine (2-HOBA) can scavenge γ-ketoaldehydes faster than they can form these adducts, thereby protecting cells and tissues from their damaging effects (Davies et al., 2002; Zagol-Ikapitte et al., 2010) . The initial evidence for 2-HOBA's protective effects against the effects of oxidative stress was established in HepG2 cells (Davies et al., 2006) , and subsequent studies have shown beneficial effects of 2-HOBA in vivo across organ systems and species. 2-HOBA attenuated markers of aging and increased lifespan in C. elegans (Nguyen et al., 2016) . In mice, 2-HOBA administration has been shown to maintain brain health and working memory in multiple mouse models with neurocognitive dysfunction (Davies et al., 2011; Pearson et al., 2017) . A protective effect of 2-HOBA against hypertension has also been observed in multiple mouse models, including angiotensin-II induced hypertension (Kirabo et al., 2014) , chronic vascular oxidative stress (Wu et al., 2016) , and genetically induced pulmonary arterial hypertension (BMPR2 mutant mice) (Egnatchik et al., 2017) .
Although most of preclinical evidence for 2-HOBA has come from disease models, oxidative damage also occurs in typical aging and other very common conditions, such as obesity (Marseglia et al., 2014; Finkel and Holbrook, 2000) . In these situations, 2-HOBA, which is naturally found in buckwheat (Koyama et al., 1971) , holds promise as nutritional supplement to help preserve good health and alleviate common comorbidities (e.g., cardiovascular events, cognitive decline).
Multiple in vitro (Fuller et al., 2018a) and rodent (Fuller et al., 2018b; Pitchford et al., 2018) safety toxicology studies of 2-HOBA have been completed with no potential safety concerns or evidence of toxic effects. However, additional information on the safety of 2-HOBA in a non-rodent species would provide valuable additional support for safe clinical trials and human use of 2-HOBA. The objective of the present study was to assess the effects of 90 days of oral 2-HOBA acetate administration in New Zealand White Rabbits.
Materials and methods

Test article
2-HOBA (as 2-hydroxybenzylamine acetate, CAS 1206675-01-5, Fig. 1 ) was provided by TSI (China) Co., Ltd. (Shanghai, China). Manufacturing Lot #16120312 was used for the present study; the purity of this lot was > 99% as measured by high-performance liquid chromatography and nuclear magnetic resonance spectroscopy. The synthetic pathway and characterization methods are considered proprietary and are therefore not described in detail. 2-HOBA acetate was dissolved in 0.1% carboxymethylcellulose (in water) at concentrations of 0, 10, 50, or 100 mg/mL. Fresh solutions were prepared daily prior to animal dosing.
Animals and protocol
This study was conducted in 2017 by Vedic Life Sciences, Pvt. Ltd. (Mumbai, India) in accordance with OECD Good Laboratory Practice (GLP) principles (OECD, 1998) and following the guidelines described in Redbook 2000 IV.C.4.b Subchronic Toxicity Studies with Non-Rodents (Office of Food Additive Safety U.S. Food and Drug Administration, 2003) . All experiments followed the National Institutes of Health Guide for the Care and use of Laboratory Animals (Guide for the Care and Use of Laboratory Animals, 2011).
Male and female 5-6-month-old New Zealand White Rabbits were used for this study. All rabbits were bred in-house at Vedic Life Sciences and were in good health at the initiation of the study. Rabbits were individually housed in stainless steel cages and provided standard laboratory rabbit diet and reverse osmosis purified drinking water ad libitum. The room temperature and relative humidity were maintained between 18.2 and 21.5°C and 43 and 55%, respectively. The light cycle was set to 12 h light/12 h dark. All rabbits were acclimatized to the testing environmental conditions for five days before initiating dosing.
Rabbits were randomly assigned to groups to minimize weight variation between groups ( ± 20% within and between groups). The study groups (n = 5/sex) were 1) water control, 2) vehicle control, 3) 
Observations
Each animal was observed twice daily for morbidity and mortality and once daily for clinical signs, such as changes in skin, fur, eyes, or mucous membranes; secretions; changes in gait, posture, or handling response; abnormal, clonic, or tonic movements, and stereotypes or bizarre behavior. Ophthalmic examinations were performed on all animals before initiating the study and in the control and high dose (1000 mg·kg BW −1 ·day −1 ) groups at the end of treatment. All animals were weighed at randomization and weekly thereafter. Food consumption was also determined weekly.
Hematology, clinical chemistry, and urinalysis
Blood was collected from the marginal ear vein for clinical chemistry, hematology, and coagulation factor analysis from on days 15 and 45 and at necropsy. Animals were fasted overnight (14-16 h) before blood collection. Hematology parameters (white blood cell count, red blood cell count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelet count, reticulocyte count, prothrombin time, activated partial thromboplastin time, neutrophils, lymphocytes, monocytes, eosinophils, and basophils) were measured using a hematology autoanalyzer (BC-2800, Mindray, Shenzhen, China). Clinical chemistry parameters (albumin, alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, calcium, chloride, cholesterol, creatinine, gamma glutamyl transferase, globulin, glucose, glutamate dehydrogenase, phosphorous, potassium, sodium, sorbitol dehydrogenase, total bilirubin, total protein, triglycerides, and urea) were measured using an automated chemistry analyzer (LWC100plus, Landwind Medical, Shenzhen, China). Urine was collected from the bladder at necropsy and evaluated for color and appearance (by observation); specific gravity, pH, protein, glucose, bilirubin, blood, leukocytes, urobilinogen, and ketones (by autoanalyzer, Uro-dipcheck TM 300, ERBA Diagnostics, Mannheim, Germany); and epithelial cells, pus cells, red blood cells, casts, crystals, and sperms (by microscopic observation).
Pathology and histopathology
Animals were euthanized on day 91 (primary groups) or day 105 (recovery groups). The adrenal glands, brain, heart, kidneys, liver, spleen, testes/ovaries, thyroid/parathyroid, and epididymis/uterus were collected, weighed, and fixed in 10% neutral formalin (with the exception of testes, which were fixed in modified Davidson's fluid). 
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Additional tissues (aorta, bone, bone marrow, brain, eyes, nasal tribunals, cecum, colon, rectum, duodenum, ileum, jejunum, lungs, esophagus, stomach, trachea, pancreas, spinal cord, sternum, thymus, Harderian gland, lymph nodes, mammary glands, salivary glands, sciatic nerve, vagina, seminal vesicles, skeletal muscle, skin, and bladder) were also fixed in 10% neutral formalin for histology.
Statistical analysis
Statistical analyses were performed on body weights, body weight changes, food consumption, hematology, clinical chemistry, urinalysis, and organ weights. The 100, 500, and 1000 mg·kg BW −1 ·day −1 groups were compared with the vehicle control group. The 1000 mg·kg BW −1 ·day −1 recovery group was compared with the vehicle recovery group. Data sets were analyzed for homogeneity of variance using Levene's test followed by the Shapiro-Wilk test for normality. A p-value of < 0.001 was required for each test to reject the null hypothesis. If the Levene's test and the Shapiro-Wilk test were both not significant, a single-factor parametric analysis of variance (ANOVA) with group as the factor was applied using an α < 0.05 level of significance. If the parametric ANOVA was significant at p < 0.05, Dunnett's test was used to identify statistically significant differences between the vehicle control and each treated group (100, 500, and 1000 mg·kg
) using an α of < 0.05. If either the Levene's test or the Shapiro-Wilk test were significant, then the Kruskal-Wallis non-parametric ANOVA with group as the factor was applied using an α < 0.05 level of significance. If the non-parametric Kruskal-Wallis ANOVA was significant at p < 0.05, Dunn's test was used to identify statistically significant differences between the vehicle control and each treated group (100, 500, and 1000 mg·kg BW −1 ·day −1 ) using an α of < 0.05.
The same decision tree was applied to determine any significant differences between the vehicle recovery and 1000 mg·kg BW −1 ·day −1 recovery groups. All data are expressed as mean ± standard deviation.
Results and discussion
Observations
All animals survived to scheduled necropsy and no morbidity was observed. No abnormal clinical, ophthalmic, or behavioral abnormalities were observed in any of the animals during the study. Body weight data are provided in Table 1 . No differences in body weight were observed between groups, and weight gain was similar between groups. The recovery high dose female rabbits gained less weight (p < 0.05) than did the recovery control female rabbits over 90 days, but the difference between groups was less than 5%. The 104-day weight gain /μL 8.8 ± 3.0 9.7 ± 2.1 8.8 ± 2.8 9.0 ± 3.2 9.7 ± 3.0 9.9 ± 2.8 9.9 ± 3.0 Neutrophil, % 17.8 ± 1.5 18.4 ± 2.1 17.8 ± 0.8 18.0 ± 2.6 18.0 ± 1.6 17.4 ± 1.1 18.2 ± 1.3 Lymphocyte, % 78.0 ± 1.6 77.4 ± 1.7 77.8 ± 1.3 77.8 ± 2.4 77.6 ± 1.8 78.2 ± 1.3 77.4 ± 1.7 Monocyte, % 2.8 ± 0.8 2.8 ± 0.5 3.4 ± 0.6 3.2 ± 0.8 2.8 ± 1.3 2.8 ± 1.3 3.0 ± 0.7 Eosinophil, % 1.0 ± 0.7 1.0 ± 0.7 0.6 ± 0.6 0.6 ± 0.6 1.2 ± 1.3 1.2 ± 1.3 1.0 ± 0.7 Basophil, % 0.4 ± 0.6 0.4 ± 0.6 0.4 ± 0.6 0.4 ± 0.6 0.4 ± 0.6 0.4 ± 0.6 0.4 ± 0.6 PT, sec 9.3 ± 0.7 9.2 ± 0.7 9.3 ± 0.7 9.0 ± 0.6 9.0 ± 0.9 9.1 ± 0.7 9.2 ± 0.6 APTT, sec 13.7 ± 1.8 13.3 ± 1.7 13.4 ± 1.7 13.2 ± 2.0 12.8 ± 1.9 13.0 ± 2.0 13.1 ± 1.5
Females RBC, × 10 6 /μL 6.0 ± 0.6 5.8 ± 0.7 6.0 ± 0.8 6.1 ± 0.7 6.1 ± 0.7 5.8 ± 0.6 5.9 ± 0.6 HCT, % 40.8 ± 2.8 41.0 ± 2.4 41.1 ± 1.9 40.6 ± 2.7 41.1 ± 2.5 40.9 ± 2.3 41.4 ± 1.8 MCV, fL 69.2 ± 3.0 68.8 ± 2.7 67.6 ± 2.3 68.6 ± 2.2 68.5 ± 2.5 68.4 ± 2.7 69.3 ± 2.2 HGB, g/dL 12.3 ± 1.6 13.1 ± 0.9 12.5 ± 1.7 12.6 ± 1.6 13.0 ± 1.5 12.5 ± 1.4 12.7 ± 1.6 MCH, pg 22.0 ± 1.0 22.1 ± 1.1 21.7 ± 1.0 22.0 ± 0.9 22.1 ± 0.9 21.7 ± 1.0 22.1 ± 1.0 MCHC, g/dL 32.4 ± 1.4 32.3 ± 1.3 32.1 ± 1.1 32. 9.2 ± 2.8 10.1 ± 2.5 9.9 ± 3.0 10.0 ± 3.0 9.7 ± 3.3 10.1 ± 2.9 10.5 ± 3.0 Neutrophil, % 16.0 ± 2.0 16.6 ± 1.3 16.4 ± 1.7 16.2 ± 1.6 17.0 ± 1.6 16.2 ± 1.9 16.6 ± 1.5 Lymphocyte, % 80.0 ± 2.0 79.4 ± 1.3 79.6 ± 1.7 79.8 ± 1.6 79.0 ± 1.6 79.8 ± 1.9 79.4 ± 1.5 Monocyte, % 3.0 ± 1.0 3.0 ± 1.2 2.8 ± 0.8 3.6 ± 0.6 2.8 ± 0. 9.5 ± 0.7 9.2 ± 0.7 9.2 ± 0.8 9.2 ± 0.6 9.3 ± 0.8 9.3 ± 0.6 9.0 ± 0.7 APTT, sec 12.8 ± 1.9 13.5 ± 2.2 13.0 ± 1.9 13.3 ± 1.8 13.7 ± 1.1 14.1 ± 1.3 13.3 ± 1.8 a Data are expressed as mean ± SD. n = 5/sex/group. b Vehicle = 0.1% carboxymethylcellulose in water. c Recovery groups received either vehicle or 1000 mg 2-HOBA acetate/kg BW for 90 days, then recovered for 14 days before euthanasia.
2-HOBA, 2-hydroxybenzylamine; APTT, activated partial thromboplastin time; BW, body weight; HCT, hematocrit; HGB, hemoglobin; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; PT, prothrombin time; RBC, red blood cell; WBC, white blood cell.
J.C. Fuller et al. Regulatory Toxicology and Pharmacology 100 (2018) [52] [53] [54] [55] [56] [57] [58] was not significantly different between groups, and there was no effect of 2-HOBA acetate on weight gain in the non-recovery females or in males. Feed consumption (Table 2 ) was similar across treatment groups.
Hematology, clinical chemistry, and urinalysis
Hematology and clinical chemistry results are presented in Tables 3  and 4 , respectively. No significant differences were observed between groups for any of the analyzed parameters following 90 days of 2-HOBA administration. Two sporadic significant differences were observed at day 15 (greater activated partial thromboplastin time in high dose recovery males; lower phosphorous in low-dose males), but these were not observed in any other dose groups, in females, or at other time points and they were considered incidental and not indicative of toxicity. No differences in urine chemistry were observed between groups (data not shown).
Pathology and histopathology
Organ weights are shown in Table 5 . Brain weight was significantly lower in high dose recovery male rabbits relative to the recovery control group, but no other effects of 2-HOBA acetate on brain weight were observed at other dose levels in males or in any female groups. No other differences in organ weights were observed.
No gross pathologies were observed in any of the experimental animals. Abnormal histopathological findings were noted in lung, liver, kidney, brain, and ileum. The incidence of findings was either similar between control and 2-HOBA acetate treated-animals or, for some findings, lower in treated animals.
In lung, parabronchial lymphoid tissue hyperplasia, alveolar thickening, and/or inflammation was noted in the lungs of most of the experimental animals, including 9/10 control, 4/10 high dose, 6/10 vehicle control, and 8/10 high dose recovery animals.
In liver, foci of mononuclear cells were observed in the periportal region in vehicle control (2/10), high dose groups (3/10), and high dose recovery groups (1/10), but not in the recovery control group. Periportal inflammation was observed in 2/10 vehicle control animals and 3/10 recovery control animals, and central lobular inflammation and necrosis were each observed in 2/10 recovery control animals and 1/10 high dose recovery animals, but no liver inflammation or necrosis were observed in the high dose animals. Tubular nephritis was observed in kidney from 1/10 vehicle control, 1/10 control recovery, and 1/10 high dose recovery group animals. Cystic degeneration was also observed in the kidney of one vehicle control animal but was not observed in the high dose group or either recovery group. In brain, thickening of the meninges was noted in 1/10 vehicle control group animals; foci of necrosis were also observed in 1/10 control recovery group animals, but no histopathological abnormalities were found in the brains of any high dose or high dose recovery animals.
In the ileum, submucosal lymphoid tissue hyperplasia was observed in 4/10 control, 2/10 high dose, 3/10 control recovery, and 3/10 high dose recovery group animals. No abnormalities were detected in any other organs.
Conclusions
There were no biologically or toxicologically significant findings observed in male or female rabbits at doses up to 1000 mg·kg BW −1 ·day −1 of 2-HOBA acetate (the highest dose tested). The human equivalent doses of 2-HOBA to those tested in this study range from 16 to 160 mg/kg, as calculated based on body surface area, as recommended by the United States Food and Drug Administration (Food and Drug Administration, 2005) . Thus, the highest tested dose translates to a dose of ∼12 g per day for a 75-kg human, which is substantially higher than the dose range anticipated for human use. The present observations in rabbit agree with the results of previous studies of 2-HOBA toxicity conducted in rodents (Fuller et al., 2018b; Pitchford et al., 2018) . In a short-term (28-day) repeated oral dosing studies in rodents, no toxicological effects were observed when mice consumed feed containing up to 0.456% 2-HOBA acetate or when rats received up to 1000 mg·kg BW −1 ·day −1 of 2-HOBA acetate by oral gavage (Pitchford et al., 2018) . Similarly, there were no toxicologically significant observations associated with doses up to 1000 mg·kg BW −1 ·day −1 of 2-HOBA acetate in a subchronic (90-day) study in rats (Fuller et al., 2018b) . In conclusion, these findings along with the lack of toxicity observed in the other studies (Fuller et al, 2018a (Fuller et al, , 2018b Pitchford et al., 2018) conducted to date support proceeding with firstin-human studies of 2-HOBA and the continued development of 2-HOBA as a functional food or dietary supplement.
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